Skip to content

13F-HR filed by CHI Advisors LLC

CHI Advisors LLC filed this 13F-HR for the quarter ended 2022-06-30, filed 2022-08-12, with 28 holding rows worth $261,836,000.

Accession
0001085146-22-003022
Filed
2022-08-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2022

A holdings report, 28 entries on the cover page, a total value of $261,836,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $261,836,000 with VALUE read as thousands by filing date, 13F file number 028-19612. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
PROMETHEUS BIOSCIENCES INC74349U108COM1,671,976$47,200,000thousands by filing date
CULLINAN THERAPEUTICS INC230031106COM3,047,609$39,070,000thousands by filing date
REPARE THERAPEUTICS INC760273102COM2,646,781$37,028,000thousands by filing date
PLIANT THERAPEUTICS INC729139105COM3,106,807$24,886,000thousands by filing date
VECTIVBIO HLDG AGH9060V101COM3,782,199$20,424,000thousands by filing date
KEZAR LIFE SCIENCES INC49372L100COM1,840,793$15,223,000thousands by filing date
2SEVENTY BIO INC COMMON STOCK901384107Stock819,672$10,820,000thousands by filing date
INOZYME PHARMA INC45790W108COM2,033,802$9,701,000thousands by filing date
COMPASS THERAPEUTICS INC20454B104COM2,829,712$7,499,000thousands by filing date
IKENA ONCOLOGY INC45175G108COM1,090,937$4,833,000thousands by filing date
PRECISION BIOSCIENCES INC74019P108COM3,003,751$4,806,000thousands by filing date
NKARTA INC65487U108COMMON STOCK358,013$4,411,000thousands by filing date
FREELINE THERAPEUTICS HLDGS35655L107SPONSORED ADS4,862,319$4,230,000thousands by filing date
OMEGA THERAPEUTICS INC68217N105COMMON STOCK1,055,882$4,012,000thousands by filing date
AKOUOS INC00973J101COM836,120$3,921,000thousands by filing date
G1 THERAPEUTICS INC3621LQ109COM767,235$3,790,000thousands by filing date
ORCHARD THERAPEUTICS PLC68570P101ADR5,307,751$3,101,000thousands by filing date
ONCORUS INC68236R103COM2,367,436$2,983,000thousands by filing date
LARIMAR THERAPEUTICS INC517125100COM1,515,148$2,970,000thousands by filing date
KEROS THERAPEUTICS INC COM492327101Stock103,429$2,858,000thousands by filing date
CORVUS PHARMACEUTICALS INC221015100COM2,214,184$2,192,000thousands by filing date
ENTRADA THERAPEUTICS INC COM29384C108Stock163,496$1,991,000thousands by filing date
OVID THERAPEUTICS INC690469101COMMON STOCK864,822$1,859,000thousands by filing date
EIGER BIOPHARMACEUTICALS INC28249U105COM190,000$1,197,000thousands by filing date
PHASEBIO PHARMACEUTICALS INC717224109COM750,000$450,000thousands by filing date
SPDR SER TR78464A870S&P BIOTECH157,000$372,000thousands by filing dateput
KEZAR LIFE SCIENCES INC49372L100COM100,000$5,000thousands by filing datecall
EIGER BIOPHARMACEUTICALS INC28249U105COM25,100$4,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001085146-22-003022this filing2022-08-12acceptance time not in the bulk data set